Research paper

Effect of soybean protein on novel cardiovascular disease risk factors: a randomized controlled trial

European Journal of Clinical Nutrition

DOI: 10.1038/ejcn.2012.186

Citations: 73

Influential: 6

Interventional (Human) Studies

Study answer

What this study found

Soy protein produced limited but favorable biomarker changes. Compared with carbohydrate, soy significantly reduced leptin (−2089.8 [−3689.3, −490.3], p=0.011) but did not significantly change E-selectin (−0.74 [−3.79, 2.30], p=0.63) or resistin (−0.02 [−1.46, 1.42], p=0.98). Compared with milk protein, soy significantly lowered E-selectin (−3.93 [−7.05, −0.81], p=0.014) but not leptin (−656.5 [−2298.2, 985.3], p=0.43) or resistin (0.71 [−0.74, 2.15], p=0.34). Most other inflammatory and endothelial biomarkers, including CRP, IL-6, TNF-a, VCAM-1, ICAM-1, thrombomodulin, and adiponectin,…

Study & population: Randomized controlled trial in adults with elevated blood pressure recruited from New Orleans, Louisiana and Jackson, Mississippi.
Intervention: Soy protein 40 g/day (89.3 mg isoflavones) was taken twice daily in water or juice for 8 weeks.
Key limitation: The intervention was short at 8 weeks and assessed biomarkers rather than clinical cardiovascular outcomes, so durability and clinical significance remain uncertain.

View source

Open PDF

Original abstract

No abstract is available for this paper.